EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

Contemporary Initial Glucose‐Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta‐Analysis

Gabriel Cavalcante Lima Chagas iD, Mayara Rios Leite Macedo Monteiro, Marina Loch Eira, Gaspar R Chiappa, Joaquim Silva Custódio, Marconi Abreu iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11862-11871

DOI: 10.1111/dom.71397 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 29.09.2026. Verfasst von Gabriel Cavalcante Lima Chagas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare contemporary initial glucose‐lowering strategies in adults with type 2 diabetes who were treatment‐naïve or had completed adequate washout. Materials and Methods We searched MEDLINE, Embase and the Cochrane Library from inception to 20 September 2025 for randomized trials comparing sodium‐glucose cotransporter 2 inhibitor (SGLT2i) monotherapy, glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) or dual incretin agonist monotherapy, SGLT2i plus metformin or placebo. Two reviewers independently selected studies and verified extracted data. Bayesian random‐effects network meta‐analysis was used.

Results

Twenty randomized trials with 8947 participants were included; all were at low risk of bias. Compared with placebo, SGLT2i plus metformin produced the largest HbA1c reduction (mean difference [MD] –1.36%, 95% credible interval [CrI] –1.91 to −0.82), followed by GLP‐1 RA or dual incretin agonist monotherapy (MD –1.25%, 95% CrI –1.68 to −0.83) and SGLT2i monotherapy (MD –0.76%, 95% CrI –1.10 to −0.41). Achievement of HbA1c < 7% and fasting plasma glucose reduction showed a similar pattern. GLP‐1 RA or dual incretin agonist monotherapy produced the greatest body weight percentage reduction (MD –4.74%, 95% CrI –6.71 to −2.90). Active‐treatment comparisons were indirect, and baseline HbA1c was higher in the SGLT2i plus metformin node. Certainty of evidence was low or very low across key comparisons.

Conclusions

SGLT2i plus metformin and GLP‐1 RA or dual incretin agonist therapy are both reasonable contemporary initial glucose‐lowering strategies for type 2 diabetes. Selection between these strategies should take into consideration phenotype, treatment priorities, tolerability, cost, access and patient preference. Trial Registration PROSPERO: CRD420251178714

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsHumansMetforminBayes TheoremDrug Therapy, CombinationGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseGlycated HemoglobinRandomized Controlled Trials as TopicIncretins

Stichwörter der Autor:innen

GLP‐1 receptor agonistsSGLT2 inhibitorsfirst‐line therapymetforminnetwork meta‐analysistype 2 diabetes

Substanzen

Hypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseGlycated HemoglobinIncretinshemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Internal Medicine, Texas Health Resources, Dallas, Texas, USA.
  • Faculdade de Medicina de Marília, Marília, São Paulo, Brazil.
  • Faculty of Health Sciences, Universidad Autónoma de Chile, Providencia, Chile.
  • Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
  • Division of Endocrinology, University of Texas Southwestern, Dallas, Texas, USA.

ORCID-Profile: Gabriel Cavalcante Lima Chagas, Marconi Abreu

Zitieren

APA

Cavalcante Lima Chagas, G., Rios Leite Macedo Monteiro, M., Eira, M. L., Chiappa, G. R., Custódio, J. S., & Abreu, M. (2026). Contemporary Initial Glucose‐Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta‐Analysis. Diabetes, Obesity and Metabolism, 28(12), 11862-11871. https://doi.org/10.1111/dom.71397

Vancouver

Cavalcante Lima Chagas G, Rios Leite Macedo Monteiro M, Eira ML, Chiappa GR, Custódio JS, Abreu M. Contemporary Initial Glucose‐Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026;28(12):11862-11871. doi:10.1111/dom.71397

BibTeX
@article{CavalcanteLimaChagas2026,
  author = {Cavalcante Lima Chagas, Gabriel and Rios Leite Macedo Monteiro, Mayara and Eira, Marina Loch and Chiappa, Gaspar R and Custódio, Joaquim Silva and Abreu, Marconi},
  title = {Contemporary Initial Glucose‐Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta‐Analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11862--11871},
  doi = {10.1111/dom.71397}
}
Kostenlos starten →